| Prev Close | 3.12 |
| Day Low/High | 3.06 / 3.17 |
| 52 Wk Low/High | 2.53 / 3.96 |
| Avg Volume | 1.06M |
Latest News
Antares Pharma Reports Second Quarter 2019 Operating And Financial Results
Record Quarterly Revenue of $28.4 Million - Double Second Quarter 2018 Revenue The Company Increases Full Year 2019 Revenue Guidance to a Range of $100.
Stocks Under $10 Weekly Summary
While the portfolio experienced some pain last week along with the broader market, 12 of our holdings beat the Russell 2000 either on an absolute or relative basis.
Stocks Under $10 Weekly Summary
We exited a position last week for a nice gain as the market continued to rise.
Stocks Under $10 Weekly Summary
As the momentum of earnings season rose last week, we made several trades including initiating a new position in Innovative Solutions and Support.
Stocks Under $10 Weekly Summary
We added to one position last week as as the small-cap heavy Russell 2000 dipped.
Stocks Under $10 Weekly Summary
We added to one position and initiated another during a shortened holiday week.
Stocks Under $10 Weekly Summary
We initiated a new position and added to a couple of others as we closed the books on the second quarter.
Interesting ATRS Put And Call Options For February 2020
Investors in Antares Pharma Inc. saw new options begin trading this week, for the February 2020 expiration.
Stocks Under $10 Weekly Summary
Last week we started two new positions, trimmed a winner and exited another name as the markets moved higher across the board.
Stocks Under $10 Weekly Summary
With the market rising last week, we saw favorable action in several of our holdings and booked some hefty gains in one name.
Stocks Under $10 Weekly Summary
With the market rebounding, the majority of our positions rose week over week.
Stocks Under $10 Weekly Summary
During the week, we exited our position in KushCo Holdings and initiated Antares Pharma.
An Initiation and an Exit
We will close out KushCo Holdings, largely replacing it with an initial position in Antares Pharma.
Adding a Specialty Pharma Name to the Bullpen
There’s enough to like about Antares Pharma to keep an eye on it.
First Week Of June 21st Options Trading For Antares Pharma (ATRS)
Investors in Antares Pharma Inc. saw new options begin trading this week, for the June 21st expiration.
Ratings Changes Today
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ALRM, ATRS, CCK, CGC, FHN, FLGT, FND, GIFI, GTS, IMKTA, IONS, IROQ, LAWS, LEG, MANH, MOFG, NMFC, NPTN, NWN, RUN, VAC, WAL, XRAY Downgrades: ACHC, CNCE, HCI, ORBC, VMW Initiations: ALTR, FNKO, SE Read on to get TheStreet Quant Ratings' detailed report:
Noteworthy Tuesday Option Activity: ATRS, ADI, CMTL
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Antares Pharma Inc. , where a total volume of 6,257 contracts has been traded thus far today, a contract volume which is representative of approximately 625,700 underlying shares (given that every 1 contract represents 100 underlying shares).
Antares Pharma Provides XYOSTED™ Regulatory Update
Complete Response Resubmission Accepted - PDUFA Date September 29, 2018
Antares Pharma Provides XYOSTED™ Regulatory Update
The Company Anticipates Second Quarter 2018 Resubmission
Antares Pharma Reports Fourth Quarter And Full Year 2017 Operating And Financial Results
Record Annual Revenue of $54.5 Million
First Week of April 20th Options Trading For Antares Pharma (ATRS)
Investors in Antares Pharma Inc. saw new options become available this week, for the April 20th expiration.
Antares Pharma Announces FDA Approval Of Partner's Product Utilizing Our QuickShot Auto Injector
AMAG Pharmaceuticals Makena® Subcutaneous Auto-Injector Approved To Reduce The Risk Of Preterm Birth In Certain At-Risk Women
